Clinical Trial Update: Efficacy and Safety of GSK Biologicals HIV Vaccine in Antiretroviral Therapy (ART)-naïve HIV-1 Infected Persons [Phase 2]

View source ↗

Summary

Phase 2 trial update on the efficacy and safety of a GSK HIV vaccine in ART-naïve HIV-1 infected persons; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Immunodeficiency Syndrome
• HIV Infection

Drugs mentioned

• GSK HIV vaccine

Snippet

Sponsor: GlaxoSmithKline | Conditions: AIDS | Phase 2 | Status: COMPLETED | Results posted: 2018-05-21